NewcelX Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.0%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.18next fiscal year
Monitoring Framework
Key Performance Indicators
NCEL-101 Pre-IND Regulatory Progress QuarterlyTarget: Type B pre-IND meeting with the FDA scheduled for the last week of June 2026
Cash and Cash Equivalents Quarterly2.2MTarget: Secure additional financing through the $25 million Equity Line of Credit or warrant exercises
AstroRx Clinical Development AnnuallyTarget: Initiation of U.S. Phase 2a clinical trial in ALS
Watch Items
- FDA Feedback on NCEL-101 Pre-IND PackageTrigger: FDA guidance on manufacturing, preclinical safety/toxicology, and first-in-human trial design following the June 2026 Type B meetingAction: Refine the IND-enabling study protocols and manufacturing processes to align with FDA requirements
- Going Concern and Capital RunwayTrigger: Cash burn rate exceeding available capital, given the substantial doubt about the company's ability to continue as a going concernAction: Draw down on the $25 million Equity Line of Credit or pursue strategic partnerships and non-dilutive funding
- Nasdaq Listing ComplianceTrigger: Failure to maintain minimum bid price or other Nasdaq Capital Market listing requirementsAction: Implement corporate actions, such as a reverse share split or capital restructuring, to maintain listing status
Research as of 20 Jun 2026